Top-News
Biotechnologie USA

Carisma Therapeutics News

Aktie
WKN:  A3DZG2 ISIN:  US14216R1014 US-Symbol:  CARM
1,10 €
+0,006 €
+0,55%
14.06.24 18:35:20
Handeln Depot/Watchlist
Aktienanzahl *
40,28 Mio.
Marktkapitalisierung *
42,92 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 27.10.2023

Carisma Therapeutics News

13.06.24 - PR Newswire
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders PR Newswire
30.05.24 - PR Newswire
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference PR Newswire
16.05.24 - PR Newswire
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-​Monocyte PR Newswire
09.05.24 - PR Newswire
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR Newswire
08.05.24 - PR Newswire
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-​Fibrotic Potential of Engineered Macrophages at ASGCT 2024 PR Newswire
06.05.24 - PR Newswire
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference PR Newswire
02.05.24 - PR Newswire
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer PR Newswire
24.04.24 - PR Newswire
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire
22.04.24 - PR Newswire
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting PR Newswire
03.04.24 - PR Newswire
Carisma Therapeutics to Present at Upcoming Conferences
Carisma Therapeutics to Present at Upcoming Conferences PR Newswire
01.04.24 - PR Newswire
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire
01.04.24 - PR Newswire
Carisma Therapeutics Announces Changes to its Board of Directors
Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire
21.03.24 - PR Newswire
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire
28.02.24 - PR Newswire
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference PR Newswire
21.12.23 - PR Newswire
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
14.12.23 - PR Newswire
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-​Moderna Collaboration PR Newswire
28.11.23 - PR Newswire
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-​Monocyte PR Newswire
22.11.23 - PR Newswire
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference PR Newswire
09.11.23 - PR Newswire
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights PR Newswire
31.10.23 - PR Newswire
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
Carisma Presents Pre-​Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC PR Newswire

Newssuche

Videos

newspaper
13.06.24 0,00%
Technical Trading: Zukauf-​Chance bei Top-Trade, wenn
Sugar No.11 Long Typ: Turbo Open End WKN: VV50DP Hebel: 5 Laufzeit: OpenEnd Einstieg: prozyklisch ... Mehr »